Neurochem withdraws Kiacta MAA
The European Medicines Agency (EMEA) has been formally notified by Canadian drugmaker Neurochem of its decision to withdraw the application for a centralized marketing authorization of its drug Kiacta (eprodisate disodium) capsules. This was under development for the treatment of amyloid A amyloidosis, a rare, life-threatening disease that occurs in patients with long-lasting inflammation, most commonly due to rheumatoid arthritis.
Could not conduct further trials in time
The application for marketing authorization for Kiacta was submitted to the EMEA on September 4, 2006. The Committee for Medicinal Products for Human Use (CHMP) had given a negative opinion recommending the refusal of marketing authorization late last year (Marketletter December 24, 2007). The company had requested a re-examination of the negative opinion, but this had not finished when it decided to withdraw its application.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze